Release date:2020/2/21 6:57:06
With the FDA's successive approval of ADC at the end of last year, this class of drugs has again become an obvious trend after a long period of time, which has given people a little more confidence in many ADC projects under development.

The following table counts 60 ADC projects under development in the global market. (If there are any omissions, readers are welcome to add them.)

Project Name Company Target Research Phase Application
mirvetuximab soravtansine ImmunoGen FRA ph3 carcinoma of fallopian tube
trastuzumab duocarmazine Synthon HER2/neu Ph3 HER2 positive metastatic breast cancer
trastuzumab maytansine Bio-Thera Solutions HER2/neu ph3 HER2 positive metastatic breast cancer
anetumab ravtansine Bayer mesothelin ph2 pancreatic cancer
tisotumab vedotin Genmab CD142 ph2 ovarian cancer
Remegen RC48 RemeGen,Ltd. HER2/neu ph2 HER2 positive metastatic breast cancer
loncsstuximab tesirine ADC Therapeutics CD19 ph2 relapsed or refractory DLBCL
camidanlumab tesirine ADC Therapeutics CD25 ph2 Hodgkin lymphoma
telisotuzumab vedotin AbbVie c-met ph2 NSCLC
belantamab mafodotin 6SK BCMA ph2 Multiple myeloma
ladiratuzumab vedotin Roche LIV1 Ph1/2 Triple Negative Breast Cancer(TNBC)
patritumab deruxtecan Daiichi Sankyo HER3 Ph1/2 HER3 positive metastatic breast cancer
BMS-986148 BMS mesothelin Ph1/2 solid tumor
enapotamab vedotin Seattle Genetics AXL Ph1/2 solid tumor
BA3011 BioAtla AXL Ph1/2 solid tumor
CX-2029 CytomX CD71 Ph1/2 solid tumor
A166 Kelun Pharmaceutical HER2/neu Ph1/2 HER2 Positive solid tumor
W0101 MSD IGF-1R Ph1/2 Metastatic solid tumor
BA3021 BioAtla ROR2 Ph1/2 solid tumor
SKB264 Kelun Pharmaceutical TROP2 Ph1/2 Metastatic solid tumor
ADCT-602 ADC Therapeutics CD22 Ph1/2 acute lymphatic leukaemia
OBI-999 Obi Pharma Globo H Ph1/2 solid tumor
DS-7300a Daiichi Sankyo B7-H3 Ph1/2 solid tumor
MORAb-202 Morphotek FRA Ph1 solid tumor
TAK-164 Takeda GCC Ph1 gastrointestinal cancer
ZW49 Zyme works HER2/neu Ph1 HER2 Positive solid tumor
TR1801-ADC Mitsubishi Tanabe c-met Ph1 solid tumor
STRO-002 Sutro FRA Ph1 endometrial cancer
JBH492 Novartis CCR7 Ph1 non-hodgkin lymphoma
DHES0815A Roche HER2/neu Ph1 HER2 positive metastatic breast cancer
NJH395 Novartis HER2/neu Ph1 HER2 positive metastatic breast cancer
VLS-101 VelosBio ROR1 Ph1 haematological cancer
F0002-ADC Fudan-Zhangjiang Bio-Pharmaceutical CD30 Ph1 CD30-positive hematological malignancies
FS-1502 Fosun Pharma HER2/neu Ph1 HER2 positive metastatic breast cancer
CC-99712 Celgene BCMA Ph1 multiple myeloma
AbGn-107 AbGenomics C071 Ph1 solid tumor
SHR-A1201 Hengrui Medicine HER2/neu Ph1 HER-2 positive recurrent metastatic breast cancer
SAR408701 Sanofi CEACAM5 Ph1/2 solid tumor
AMG 224 Amgen BCMA Ph1/2 multiple myeloma
IMGN632 ImmunoGen CD123 Ph1/2 acute myelogenous leukemia
STRO001 Sutro Biopharma CD74 Ph1 B-cell Lymphoma
tabituximab barzuxetan Oncotherapy FZD10 Ph1 synovialoma
ARX788 Zhejiang Pharmaceutical
HER2/neu IgGl HER2 Positive solid tumor
cofetuzumab pelidotin Pfizer, StemCentRx PTK7 IgGl triple-negative breast cancer(TNBC)
OBT076 Oxford Bio CD205 IgGl triple-negative breast cancer(TNBC)
I6N002 ImmunGene CD20 IgGl non-hodgkin lymphoma
AGS67E Agensys, Astellas CD37 Ph1 lymphoma
PCA062 Novartis P-cadherin Ph1 P-cadherin Positive solid tumor
MEDI3726 ADC Therapeutics PSMA Ph1 Prostate-specific membrane antigen (PSMA)
DS-1062a Daiichi Sankyo TTIOP2 Ph1 NSCLC
MEDI4276 Astrazeneca HER2/neu Ph1 HER2 Positive solid tumor
AGS62P1 Agensys, Astellas FLT3 Ph1 acute lymphatic leukaemia
XMT-1522 Mersana HER2/neu Ph1 solid tumor
XMT-1536 Mersana NaPi2b Ph1 solid tumor
SHR-A1403 Hengrui Medicine c.met Ph1 solid tumor
MEDI7247 Astrazeneca ASCT2 Ph1 haematological cancer
SYD1875 Synthon TPBG Ph1 solid tumor
iladatuzumab vedotin Roche CD79b Ph1 non-hodgkin lymphoma
MEDI2228 Astrazeneca BCMA Ph1 multiple myeloma
TRPH-222 Triphase CD22 Ph1 B-cell Lymphoma

HER2 / neu can be described as one of the most classic targets in the history of antibody drug development. Monoclonal antibodies against this target have undergone many iterative updates. The development of derived bispecific antibodies and ADC is also in full swing.

BCMA is the main target of multiple myeloma and competition is fierce. In addition to the intra-field competition between many ADCs, there are external competitions from CAR-T cell therapy, and the market prospects are relatively complex. From the perspective of cost alone, the odds of ADC drugs are undoubtedly greater, but as a treatment method, clinical effect is the decisive factor.

c-met is also a classic target. Roche invested in this target for a long time and eventually failed. There may be many reasons, including c-met expression profiles, antibody design problems, and so on. At present, there are two mainstream R & D strategies for c-met: one is ADC, and the other is c-met / EGFR bispecific antibody. There are also some research institutions trying to use CAR-T treatment.

Of course, there are also many innovative targets on the pipeline, such as TROP2, AXL, etc. It is expected that the potential of these targets can be fully demonstrated, providing more options for clinical treatment.

Related Article:
Cleavable vs. Non-Cleavable Linkers in Antibody-Drug Conjugates
ADCs Against Cancer: Clinical Landscape and Challenges
History and Development of Antibody Drug Conjugates (ADCs)
Anti-Cancer ADC Drugs: 3 Design Elements, 7 Approved ADCs, Multiple Clinical Trials

Previous:What Are ADC Linkers: Cleavable vs. Non-Cleavable Linkers Next:FDA Approves Sacituzumab Govitecan for Triple-Negative Breast Cancer